KPT 8602

Drug Profile

KPT 8602

Alternative Names: KPT-8602

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Prostate cancer

Most Recent Events

  • 12 Oct 2017 KPT 8602 licensed to Ono Pharmaceutical in Japan, South Korea, Taiwan, Hong Kong, and South East Asia (ASEAN countries)
  • 01 Apr 2017 Pharmacokinetics and pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Mar 2017 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater) in USA, Canada (PO) before March 2017 (Karyopharm Therapeutics pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top